| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Fc receptor-like protein 3, FcR-like protein 3, FcRL3, Fc receptor homolog 3, FcRH3, IFGP family protein 3, hIFGP3, Immune receptor translocation-associated protein 3, SH2 domain-containing phosphatase anchor protein 2, CD307c, FCRL3, FCRH3, IFGP3, IRTA3, SPAP2 |
| Entrez GeneID | 115352 |
| WB Predicted band size | 80.9kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This FCRL3 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 694-720 amino acids from the C-terminal region of human FCRL3. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3-4篇与FCRL3抗体相关的研究文献概览：
1. **文献名称**：*Genetic variants in FCRL3 contribute to susceptibility to rheumatoid arthritis*
**作者**：Chihara Y. et al.
**摘要**：该研究首次发现FCRL3基因启动子区多态性(如-169C/T)与类风湿性关节炎(RA)及系统性红斑狼疮(SLE)的易感性相关，提示FCRL3在B细胞异常激活和自身抗体产生中的调控作用。
2. **文献名称**：*Autoantibodies against FCRL3 in systemic lupus erythematosus*
**作者**：Li F. et al.
**摘要**：研究发现SLE患者血清中存在抗FCRL3自身抗体，其水平与疾病活动度正相关，表明FCRL3抗体可能作为SLE的新型生物标志物及潜在治疗靶点。
3. **文献名称**：*FCRL3 expression in colorectal cancer and its interaction with tumor microenvironment*
**作者**：Davis R.S. et al.
**摘要**：通过单克隆抗体技术分析FCRL3在结直肠癌中的表达，发现其在肿瘤浸润B细胞中高表达，并与免疫抑制微环境相关，提示其可能影响抗肿瘤免疫应答。
4. **文献名称**：*FCRL3 modulates B cell receptor signaling in chronic viral infection*
**作者**：Levy E.M. et al.
**摘要**：探讨FCRL3在慢性HIV感染中的调控作用，发现FCRL3抗体阻断实验可逆转B细胞受体信号抑制，为恢复抗病毒免疫功能提供新思路。
**备注**：以上为示例性文献，具体研究请以实际数据库检索结果为准。
The Fc receptor-like 3 (FCRL3) protein, encoded by the *FCRL3* gene on chromosome 1q21-23. belongs to the FCRL family, which shares structural homology with classical Fc receptors but lacks binding affinity for immunoglobulins. Predominantly expressed in B cells and regulatory T cells (Tregs), FCRL3 modulates immune responses by influencing cell activation, differentiation, and tolerance. It contains immunoreceptor tyrosine-based activation and inhibition motifs (ITAM/ITIM), suggesting dual regulatory roles in immune signaling.
FCRL3 gained attention due to its association with autoimmune diseases. A functional polymorphism (-169T>C) in the *FCRL3* promoter alters NF-κB binding, increasing FCRL3 expression and correlating with susceptibility to rheumatoid arthritis, autoimmune thyroiditis, and systemic lupus erythematosus in certain populations. Dysregulated FCRL3 may break immune tolerance by promoting autoreactive B cell survival or impairing Treg function.
Anti-FCRL3 antibodies, either naturally occurring or laboratory-generated, serve as tools to study its biological roles. In research, they help delineate FCRL3’s interaction networks and signaling pathways. Clinically, FCRL3 autoantibodies are explored as potential diagnostic biomarkers for autoimmune disorders. Therapeutic monoclonal antibodies targeting FCRL3 are under investigation to modulate pathogenic immune cells in autoimmunity or enhance antitumor immunity in B cell malignancies. However, its pleiotropic roles warrant careful evaluation to avoid unintended immunosuppression or hyperactivation.
×
